Recent advancements in respiratory system pharmacotherapeutics have significantly enhanced patient outcomes, enabling the development of personalized treatment plans and innovative drug delivery methods. These advancements have notably improved the management of respiratory disorders. Key developments include biologic therapies that target specific molecular pathways to modulate immune responses and inflammation, and small molecule inhibitors offering highly targeted treatments for specific respiratory conditions. Additionally, state-of-the-art inhalation technologies have been developed to optimize drug delivery, improving both efficacy and patient adherence. However, challenges remain, such as the high costs associated with these therapies, which limit healthcare equity and accessibility, the complexity of personalized medicine requiring a deep understanding of individual patient needs, and safety concerns that necessitate vigilant monitoring and preventive measures. Overcoming these challenges is essential to fully realizing the benefits of these advancements and further improving patient care.
Artificial intelligence, Biologic therapies, Drug delivery
Barnes, P. J. (2013). Personalized medicine and asthma. Respirology, 18(4), 591-599. https://doi.org/10.1111/resp.12056
Bush, A., Saglani, S., & Lloyd, C. M. (2017). Therapeutic approaches to asthma-chronic obstructive pulmonary disease overlap syndromes. Journal of Allergy and Clinical Immunology, 140(3), 710-715. https://doi.org/10.1016/j.jaci.2017.06.014
Chung, K. F., & Barnes, P. J. (2008). Pharmacogenomics in asthma therapy: Where are we and where do we go? Journal of Allergy and Clinical Immunology, 121(1), 30-37. https://doi.org/10.1016/j.jaci.2007.10.048
Fahy, J. V. (2015). Type 2 inflammation in asthma—Present in most, absent in many. Nature Reviews Immunology, 15(1), 57-65. https://doi.org/10.1038/nri3786
Global Initiative for Asthma (GINA). (2021). Global strategy for asthma management and prevention. Retrieved from https://ginasthma.org/gina-reports/
Global Initiative for Asthma (GINA). (2021). Global strategy for asthma management and prevention. Retrieved from https://ginasthma.org/gina-reports/
Global Initiative for Chronic Obstructive Lung Disease (GOLD). (2022). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Retrieved from https://goldcopd.org/
Global Initiative for Chronic Obstructive Lung Disease (GOLD). (2022). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Retrieved from https://goldcopd.org/
Kuruvilla, M. E., & Rothenberg, M. E. (2010). Development and maintenance of eosinophilic inflammation in asthma. Immunology and Allergy Clinics of North America, 30(3), 425-442.https://doi.org/10.1016/j.iac.2010.03.006
Leung, J. M., & FitzGerald, J. M. (2020). Novel therapies for severe asthma. World Allergy Organization Journal, 13(8), 100450. https://doi.org/10.1016/j.waojou.2020.100450
Lipson, D. A., & Barnhart, F. (2018). Once-daily single-inhaler triple versus dual therapy in patients with COPD. New England Journal of Medicine, 378(18), 1671-1680. https://doi.org/10.1056/NEJMoa1716201
Martinez, F. J., & Wang, C. (2013). Immunobiology of mild asthma: Regulation by dendritic cells and bronchial epithelial cells. Pulmonary Pharmacology & Therapeutics, 26(5), 473-476. https://doi.org/10.1016/j.pupt.2013.06.002
Mendell, M. J., & Rhoads, K. S. (2019). Overview of the clinical use of biologics in asthma. Annals of Allergy, Asthma & Immunology, 122(4), 373-378. https://doi.org/10.1016/j.anai.2019.01.018
Miravitlles, M., &Mazzola, P. (2012). Phenotyping chronic obstructive pulmonary disease: A step forward. European Respiratory Journal, 40(5), 1033-1041. https://doi.org/10.1183/09031936.00077311
Moller, G. M., &Watz, H. (2018). Precision medicine in airway diseases: Moving to clinical practice. European Respiratory Review, 27(145), 170121. https://doi.org/10.1183/16000617.0121-2017
Nunes, T., & Moreira, A. (2020). Emerging therapeutic approaches for idiopathic pulmonary fibrosis. Journal of Clinical Medicine, 9(10), 3189. https://doi.org/10.3390/jcm9103189
O'Sullivan, B. P., &Sandford, A. J. (2018). Precision medicine in COPD: The path forward. Current Opinion in Pulmonary Medicine, 24(2), 138-145. https://doi.org/10.1097/MCP.0000000000000456
Peters, M. C., & Wenzel, S. E. (2016). Biomarkers of exacerbation risk in adults with asthma. Clinical & Experimental Allergy, 46(8), 1025-1037. https://doi.org/10.1111/cea.12731
Peters, M. C., Mauger, D., Ross, K. R., Phillips, B., Gaston, B., Cardet, J. C., ...& Israel, E. (2019). Evidence for exacerbation-prone asthma and predictive biomarkers of exacerbation frequency. American Journal of Respiratory and Critical Care Medicine, 199(8), 980-988. https://doi.org/10.1164/rccm.201812-2277OC
Rabe, K. F., Martinez, F. J., Ferguson, G. T., Wang, C., Singh, D., Wedzicha, J. A., ...& Staudinger, H. (2020). Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. New England Journal of Medicine, 383(1), 35-48. https://doi.org/10.1056/NEJMoa1916338
Schleich, F., & Louis, R. (2018). Targeted therapies in severe asthma: What is the impact of phenotyping? Current Opinion in Pulmonary Medicine, 24(1), 4-10. https://doi.org/10.1097/MCP.0000000000000421
Siddiqui, S., &Brightling, C. E. (2011). Recent advances in asthma genetics. Current Opinion in Pulmonary Medicine, 17(1), 29-34. https://doi.org/10.1097/MCP.0b013e3283429b1d
Stockley, R. A., Halpin, D. M., Celli, B. R., Singh, D., &Wedzicha, J. A. (2021). Preventing COPD exacerbations: What is the current evidence? European Respiratory Review, 30(160), 200226. https://doi.org/10.1183/16000617.0226-2020
Wenzel, S. E. (2007). Biological mechanisms underlying the phenotype of severe asthma. The Journal of Allergy and Clinical Immunology, 119(6), 1306-1311. https://doi.org/10.1016/j.jaci.2007.03.004
Wenzel, S. E. (2012). Asthma phenotypes: The evolution from clinical to molecular approaches. Nature Medicine, 18(5), 716-725. https://doi.org/10.1038/nm.2757
